CY1109760T1 - Παραγωγα ινδολης-3-θειου - Google Patents
Παραγωγα ινδολης-3-θειουInfo
- Publication number
- CY1109760T1 CY1109760T1 CY20101100086T CY101100086T CY1109760T1 CY 1109760 T1 CY1109760 T1 CY 1109760T1 CY 20101100086 T CY20101100086 T CY 20101100086T CY 101100086 T CY101100086 T CY 101100086T CY 1109760 T1 CY1109760 T1 CY 1109760T1
- Authority
- CY
- Cyprus
- Prior art keywords
- indolis
- producers
- sulfur
- sulfur producers
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Abstract
Η παρούσα εφεύρεση αναφέρεται σε υποκατεστημένες ινδόλες χρήσιμες ως φαρμακευτικές ενώσεις για την αντιμετώπιση αναπνευστικών διαταραχών.(Ι)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202241A SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Novel Compounds |
SE0203713A SE0203713D0 (sv) | 2002-07-17 | 2002-12-13 | Novel compounds |
EP03764279A EP1551802B1 (en) | 2002-07-17 | 2003-07-15 | Indole-3-sulphur derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109760T1 true CY1109760T1 (el) | 2014-09-10 |
Family
ID=30117585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100086T CY1109760T1 (el) | 2002-07-17 | 2010-01-28 | Παραγωγα ινδολης-3-θειου |
Country Status (23)
Country | Link |
---|---|
US (2) | US7723373B2 (el) |
EP (1) | EP1551802B1 (el) |
JP (3) | JP4791729B2 (el) |
CN (1) | CN1279023C (el) |
AR (1) | AR040498A1 (el) |
AT (1) | ATE450506T1 (el) |
AU (1) | AU2003251260B2 (el) |
BR (1) | BR0312729A (el) |
CA (1) | CA2492445A1 (el) |
CY (1) | CY1109760T1 (el) |
DE (1) | DE60330372D1 (el) |
DK (1) | DK1551802T3 (el) |
ES (1) | ES2335491T3 (el) |
IL (1) | IL166121A0 (el) |
MX (1) | MXPA05000646A (el) |
NO (1) | NO20050828L (el) |
NZ (1) | NZ537606A (el) |
PT (1) | PT1551802E (el) |
SE (2) | SE0202241D0 (el) |
SI (1) | SI1551802T1 (el) |
TW (1) | TW200404778A (el) |
WO (1) | WO2004007451A1 (el) |
ZA (1) | ZA200500170B (el) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
JP4845730B2 (ja) | 2003-07-17 | 2011-12-28 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
US20070232681A1 (en) * | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
CN1930162B (zh) | 2004-03-11 | 2010-06-16 | 埃科特莱茵药品有限公司 | 四氢吡啶并吲哚衍生物 |
GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
CA2577748A1 (en) * | 2004-08-26 | 2006-03-02 | Actelion Pharmaceuticals Ltd | 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists |
CA2581338A1 (en) | 2004-09-21 | 2006-03-30 | Athersys, Inc. | Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof |
SI1809602T1 (sl) * | 2004-10-27 | 2009-04-30 | Janssen Pharmaceutica Nv | Indolni derivati, uporabni kot modulatorji progesteronskega receptorja |
UY29223A1 (es) | 2004-11-23 | 2006-06-30 | Astrazeneca Ab | Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación |
EP1833787A2 (en) * | 2004-11-30 | 2007-09-19 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
WO2006060456A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar ppar active compounds |
CA2594280C (en) | 2004-12-27 | 2013-04-23 | Anja Fecher | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
MX2007010112A (es) * | 2005-02-25 | 2007-10-12 | Ono Pharmaceutical Co | Compuesto indol y uso del mismo. |
GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
WO2007010964A1 (ja) | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するインドール誘導体 |
US7842692B2 (en) | 2005-07-22 | 2010-11-30 | Shionogi & Co., Ltd. | Azaindole derivative having PGD2 receptor antagonistic activity |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US20080234349A1 (en) * | 2005-09-07 | 2008-09-25 | Jack Lin | PPAR active compounds |
AU2006287521A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
JP5155171B2 (ja) | 2005-10-06 | 2013-02-27 | アストラゼネカ・アクチエボラーグ | 新規化合物 |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0526257D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
EP2037967B1 (en) | 2006-06-16 | 2016-12-07 | The Trustees Of The University Of Pennsylvania | Prostaglandin d2 receptor antagonists for treating androgenetic alopecia |
DK2046740T3 (da) | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
SI2051962T1 (sl) | 2006-08-07 | 2012-02-29 | Actelion Pharmaceuticals Ltd | Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
GB0722055D0 (en) * | 2007-11-09 | 2007-12-19 | Argenta Discovery Ltd | Compounds |
PT2327693E (pt) | 2007-12-14 | 2012-07-24 | Pulmagen Therapeutics Asthma Ltd | Indoles e sua utilização terapêutica |
WO2009090414A1 (en) * | 2008-01-18 | 2009-07-23 | Oxagen Limited | Compounds having crth2 antagonist activity |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
EP2240444A1 (en) | 2008-01-22 | 2010-10-20 | Oxagen Limited | Compounds having crth2 antagonist activity |
JP2011509990A (ja) | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
TWI469965B (zh) | 2008-12-22 | 2015-01-21 | Ono Pharmaceutical Co | 乙炔基吲哚化合物 |
BR112012000353B1 (pt) * | 2009-07-06 | 2020-06-02 | Astrazeneca Ab | Composto de fórmula markush, uso do composto, processos de reação com agente de acetilação e processo para preparação de um composto |
WO2011055270A1 (en) | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
AR079492A1 (es) | 2009-12-23 | 2012-02-01 | Ironwood Pharmaceuticals Inc | Moduladores de crth2 |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
KR101444572B1 (ko) | 2010-03-22 | 2014-09-24 | 액테리온 파마슈티칼 리미티드 | 3-(헤테로아릴-아미노)-1,2,3,4-테트라히드로-9h-카르바졸 유도체 및 이의 프로스타글란딘 d2 수용체 조절제로서의 용도 |
TW201229038A (en) | 2010-06-21 | 2012-07-16 | Ono Pharmaceutical Co | Novel crystalline form of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylpheny)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid |
WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2012009134A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
NZ609955A (en) | 2010-11-09 | 2015-05-29 | Ironwood Pharmaceuticals Inc | Sgc stimulators |
ES2596581T3 (es) | 2011-04-14 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético y su uso como moduladores del receptor de prostaglandina D2 |
JP6054600B2 (ja) * | 2011-08-11 | 2016-12-27 | 富士通コンポーネント株式会社 | コネクタ |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
CA2867901A1 (en) | 2012-03-21 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
WO2014047111A1 (en) | 2012-09-18 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
EP2897953B8 (en) | 2012-09-19 | 2019-06-26 | Cyclerion Therapeutics, Inc. | Sgc stimulators |
SI3660013T1 (sl) | 2013-03-15 | 2022-05-31 | Cyclerion Therapeutics, Inc. | SGC stimulatorji |
EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
MY179356A (en) | 2014-03-17 | 2020-11-05 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
CA2938107A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3194382B1 (en) | 2014-09-17 | 2021-09-08 | Cyclerion Therapeutics, Inc. | Pyrazole derivatives as sgc stimulators |
JP2017527604A (ja) | 2014-09-17 | 2017-09-21 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | sGC刺激剤 |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
KR20180031019A (ko) | 2015-07-30 | 2018-03-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Pgd2에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 dp―2 유전자의 단일 뉴클레오티드 다형성 대립유전자 |
TWI711616B (zh) | 2015-09-15 | 2020-12-01 | 瑞士商愛杜西亞製藥有限公司 | 結晶型式 |
AU2017291826B2 (en) | 2016-07-07 | 2021-10-21 | Cyclerion Therapeutics, Inc. | Phosphorus prodrugs of sGC stimulators |
EP3481820B1 (en) | 2016-07-07 | 2023-10-18 | Cyclerion Therapeutics, Inc. | Solid forms of an sgc stimulator |
WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US741360A (en) * | 1899-11-13 | 1903-10-13 | William M Moseley | Toy. |
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
NZ222878A (en) * | 1986-12-17 | 1991-02-26 | Merck Frosst Canada Inc | 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions |
US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
CA2079374C (en) * | 1991-09-30 | 2003-08-05 | Merck Frosst Canada Incorporated | (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
BR9405737A (pt) | 1993-02-24 | 1995-12-05 | Merck & Co Inc | Composto processo de inibição de transcriptase reserva de HIV, processo de prevenção contra a infecção pelo HIV ou de tratamento da infecção pelo HIV, composição farmacêutica útil para a inibição da transcriptase reserva de HIV, e, útil para a prevenção ou tratamento de infecção pelo HIV ou para o tratamento da AIDS ou ARC |
US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
US5567711A (en) * | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
WO1999009007A1 (en) | 1997-08-21 | 1999-02-25 | American Home Products Corporation | Solid phase synthesis of 2,3-disubstituted indole compounds |
WO1999032482A1 (en) | 1997-12-19 | 1999-07-01 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
AU5886500A (en) | 1999-06-23 | 2001-01-09 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
AU7962200A (en) | 1999-10-29 | 2001-05-14 | Wakunaga Pharmaceutical Co., Ltd | Novel indole derivatives and drugs containing the same as the active ingredient |
CA2699568C (en) | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
WO2002000216A1 (en) * | 2000-06-28 | 2002-01-03 | Teva Pharmaceutical Industries Ltd. | Carvedilol |
US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
PL370342A1 (en) * | 2001-09-27 | 2005-05-16 | F.Hoffmann-La Roche Ag | Indole derivatives as cox ii inhibitors |
TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
RU2337909C2 (ru) | 2002-02-01 | 2008-11-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
US20070232681A1 (en) | 2003-10-14 | 2007-10-04 | Oxagen Limited | Compounds Having Crth2 Antagonist Activity |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
RU2008152763A (ru) | 2006-06-08 | 2010-07-20 | Ньюроки А/С (Dk) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии |
KR20090023645A (ko) | 2006-06-28 | 2009-03-05 | 사노피-아벤티스 | 신규한 cxcr2 억제제 |
-
2002
- 2002-07-17 SE SE0202241A patent/SE0202241D0/xx unknown
- 2002-12-13 SE SE0203713A patent/SE0203713D0/xx unknown
-
2003
- 2003-07-07 TW TW092118486A patent/TW200404778A/zh unknown
- 2003-07-15 AU AU2003251260A patent/AU2003251260B2/en not_active Expired - Fee Related
- 2003-07-15 AT AT03764279T patent/ATE450506T1/de active
- 2003-07-15 NZ NZ537606A patent/NZ537606A/en unknown
- 2003-07-15 MX MXPA05000646A patent/MXPA05000646A/es unknown
- 2003-07-15 US US10/521,325 patent/US7723373B2/en not_active Expired - Fee Related
- 2003-07-15 JP JP2004521364A patent/JP4791729B2/ja not_active Expired - Fee Related
- 2003-07-15 BR BR0312729-0A patent/BR0312729A/pt not_active IP Right Cessation
- 2003-07-15 CN CNB038199718A patent/CN1279023C/zh not_active Expired - Fee Related
- 2003-07-15 ES ES03764279T patent/ES2335491T3/es not_active Expired - Lifetime
- 2003-07-15 EP EP03764279A patent/EP1551802B1/en not_active Expired - Lifetime
- 2003-07-15 PT PT03764279T patent/PT1551802E/pt unknown
- 2003-07-15 SI SI200331737T patent/SI1551802T1/sl unknown
- 2003-07-15 DE DE60330372T patent/DE60330372D1/de not_active Expired - Lifetime
- 2003-07-15 WO PCT/SE2003/001216 patent/WO2004007451A1/en active Application Filing
- 2003-07-15 CA CA002492445A patent/CA2492445A1/en not_active Abandoned
- 2003-07-15 DK DK03764279.0T patent/DK1551802T3/da active
- 2003-07-17 AR AR20030102585A patent/AR040498A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 IL IL16612105A patent/IL166121A0/xx unknown
- 2005-01-07 ZA ZA200500170A patent/ZA200500170B/xx unknown
- 2005-02-16 NO NO20050828A patent/NO20050828L/no not_active Application Discontinuation
-
2010
- 2010-01-28 CY CY20101100086T patent/CY1109760T1/el unknown
- 2010-04-12 US US12/758,348 patent/US20100197756A1/en not_active Abandoned
- 2010-07-23 JP JP2010166138A patent/JP2010280680A/ja not_active Withdrawn
-
2011
- 2011-03-01 JP JP2011043693A patent/JP2011116770A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
SE0202241D0 (sv) | 2002-07-17 |
EP1551802B1 (en) | 2009-12-02 |
BR0312729A (pt) | 2005-05-10 |
AU2003251260A1 (en) | 2004-02-02 |
TW200404778A (en) | 2004-04-01 |
CN1678579A (zh) | 2005-10-05 |
ES2335491T3 (es) | 2010-03-29 |
DE60330372D1 (de) | 2010-01-14 |
AU2003251260B2 (en) | 2007-04-26 |
IL166121A0 (en) | 2006-01-15 |
MXPA05000646A (es) | 2005-06-02 |
CA2492445A1 (en) | 2004-01-22 |
CN1279023C (zh) | 2006-10-11 |
US7723373B2 (en) | 2010-05-25 |
ATE450506T1 (de) | 2009-12-15 |
DK1551802T3 (da) | 2010-03-15 |
PT1551802E (pt) | 2010-02-02 |
JP2005537265A (ja) | 2005-12-08 |
US20100197756A1 (en) | 2010-08-05 |
WO2004007451A1 (en) | 2004-01-22 |
US20060111426A1 (en) | 2006-05-25 |
NO20050828L (no) | 2005-04-05 |
JP4791729B2 (ja) | 2011-10-12 |
ZA200500170B (en) | 2006-02-22 |
SE0203713D0 (sv) | 2002-12-13 |
SI1551802T1 (sl) | 2010-03-31 |
NZ537606A (en) | 2006-08-31 |
EP1551802A1 (en) | 2005-07-13 |
JP2010280680A (ja) | 2010-12-16 |
JP2011116770A (ja) | 2011-06-16 |
AR040498A1 (es) | 2005-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109760T1 (el) | Παραγωγα ινδολης-3-θειου | |
CY1109104T1 (el) | 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου | |
SE0303180D0 (sv) | Novel compounds | |
SE0302232D0 (sv) | Novel Compounds | |
SE0201635D0 (sv) | Novel compounds | |
EA200601798A1 (ru) | Замещенные соединения морфолина для лечения расстройств центральной нервной системы | |
CY1105994T1 (el) | Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων | |
CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης | |
MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
TNSN06012A1 (en) | Emulsifying systems containing azetidine derivatives | |
NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200401289A1 (ru) | Новые противоинфекционные соединения, способы их получения и фармацевтические композиции, содержащие эти соединения | |
DE60316128D1 (de) | N-sulfonylurea-apoptosis-förderer | |
EA200501925A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200602083A1 (ru) | Новые пиперазиновые производные диалкилоксиндолов | |
EA200600455A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200600456A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200600454A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200602080A1 (ru) | Пиперазиновые производные алкилоксиндолов | |
EA200602082A1 (ru) | Производные индол-2-она для лечения расстройств центральной нервной системы, желудочно-кишечных расстройств и сердечно-сосудистых расстройств |